Skip to main content
Premium Trial:

Request an Annual Quote

'Improved Pharma Demand' Helps Waters' Q4 Sales Surge 17 Percent

NEW YORK (GenomeWeb News) — Waters today said fourth-quarter 2006 revenues increased 17 percent on strong pharma demand as R&D spending rose 17 percent and profit widened 6 percent.
 
Total receipts for the three months ended Dec. 31, 2006, increased to $387 million from $332 million year over year. 
 
CEO Douglas Berthiaume said most of the revenue surge came from “improved pharmaceutical demand, continued growth in our overseas markets, and strong sales growth by our TA instruments division.”
 
Foreign currency translation was responsible for 3 percent of the increased revenue, the company said.
 
R&D spending increased to $19.5 million from $16.7 million year over year.
 
Waters said profits for the quarter grew to $78.9 million from $75.6 million in the year-ago period.
 
Waters said it had around $514.2 million in cash and equivalents as of Dec. 31, 2006.

The Scan

Rare Genetic Disease Partnership

A public-private partnership plans to speed the development of gene therapies for rare genetic diseases, Stat News writes.

Approval Sought for Alzheimer's Drug

The Wall Street Journal reports Eli Lilly has initiated a rolling submission to the US Food and Drug Administration to seek approval for its drug to treat Alzheimer's disease.

DNA Barcoding Paper Retracted

Science reports that a 2014 DNA barcoding paper was retracted after a co-author brought up data validity concerns.

Nature Papers Present Genomic Analysis of Bronze Age Mummies, Approach to Study Host-Pathogen Interactions

In Nature this week: analysis finds Tarim mummies had local genetic origin, and more.